Bristol Myers Squibb (CELG-RI) Depreciation & Amortization (CF) (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Depreciation & Amortization (CF) for 18 consecutive years, with $594.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) fell 41.25% year-over-year to $594.0 million; the TTM figure through Jun 2026 stood at $3.2 billion (down 51.1% YoY), while the FY2025 annual figure was $4.0 billion, down 58.22% from the prior year.
• Depreciation & Amortization (CF) held at $594.0 million in Q2 2026 per CELG-RI's latest filing, from $594.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.6 billion in Q2 2024 and bottomed at $594.0 million in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $1.9 billion across 5 years, with a median of $2.4 billion in 2023.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) climbed 6.74% — and 2025, when it sank 61.06%.
• Bristol Myers Squibb's Depreciation & Amortization (CF) stood at $2.5 billion in 2022, then fell by 2.26% to $2.5 billion in 2023, then declined by 23.7% to $1.9 billion in 2024, then plunged by 48.03% to $977.0 million in 2025, then slumped by 39.2% to $594.0 million in 2026.
• Business Quant data shows CELG-RI's Depreciation & Amortization (CF) at $594.0 million in Q2 2026, $594.0 million in Q1 2026, and $977.0 million in Q4 2025.